Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety

被引：3
|
作者：
Kuderer, Nicole M. [1 ]
Lyman, Gary H. [2 ]
机构：
[1] Adv Canc Res Grp, Seattle, WA 98101 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 18期
关键词：
SYMPTOMATIC ADVERSE EVENTS; PATIENT-REPORTED OUTCOMES; BREAST-CANCER; END-POINTS; ACCELERATED APPROVAL; CLINICAL-TRIALS; RESPONSE RATE; SUPPRESSION; TAMOXIFEN; ENTITIES;
D O I：
10.1200/JCO.2018.78.5592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1773 / +
页数：5
相关论文
共 50 条
  • [1] Comparison of Oncology Drug Approval Between Health Canada and the US Food and Drug Administration
    Ezeife, Doreen A.
    Truong, Tony H.
    Heng, Daniel Y. C.
    Bourque, Sylvie
    Welch, Stephen A.
    Tang, Patricia A.
    [J]. CANCER, 2015, 121 (10) : 1688 - 1693
  • [2] Evaluation and Regulation of Oncology Drug Approval Finding the Right Balance
    Lyman, Gary H.
    [J]. JAMA ONCOLOGY, 2016, 2 (06) : 728 - 729
  • [3] Oncology Drug Development and Approval of Systemic Anticancer Therapy by the US Food and Drug Administration
    Martell, Robert E.
    Sermer, David
    Getz, Kenneth
    Kaitin, Kenneth I.
    [J]. ONCOLOGIST, 2013, 18 (01): : 104 - 111
  • [4] US Food and Drug Administration and Design of Drug Approval Studies
    Woloshin, Steven
    Schwartz, Lisa M.
    Frankel, Brittney
    Faerber, Adrienne
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (20): : 2163 - 2165
  • [5] Comparison of drug approval between health Canada (HC) and the US Food and Drug Administration (FDA).
    Ezeife, Doreen Anuli
    Tang, Patricia
    Heng, Daniel Yick Chin
    Welch, Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Benefit-Risk Assessments at the US Food and Drug Administration Finding the Balance
    Califf, Robert M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (07): : 693 - 694
  • [7] US Food and Drug Administration approval of esketamine and brexanolone
    Cristea, Ioana A.
    Naudet, Florian
    [J]. LANCET PSYCHIATRY, 2019, 6 (12): : 975 - 977
  • [8] Tracking the FDA precision oncology drug approval landscape in OncoKB.
    Suehnholz, Sarah Phillips
    Kundra, Ritika
    Zhang, Hongxin
    Nissan, Moriah H.
    Lu, Calvin
    Dhaneshwar, Amanda
    Fernandez, Nicole
    Nandakumar, Subhiksha
    Arcila, Maria E.
    Ladanyi, Marc
    Berger, Michael F.
    Syed, Aijazuddin
    Brannon, Angela Rose
    Levine, Ross L.
    Dogan, Ahmet
    Drilon, Alexander E.
    Solit, David B.
    Schultz, Nikolaus
    Chakravarty, Debyani
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
    Johnson, John R.
    Ning, Yang-Min
    Farrell, Ann
    Justice, Robert
    Keegan, Patricia
    Pazdur, Richard
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (08) : 636 - 644
  • [10] US Food and Drug Administration gets it right
    Grove, ML
    [J]. BRITISH MEDICAL JOURNAL, 2002, 325 (7367): : 776 - 776
12345